

#### Prostatic urethral lift

We provide coverage for this procedure for adult members who meet medical necessity criteria. Submit authorization requests through the e-referral system.

The submitter will receive a prompt to complete a questionnaire to determine the appropriateness of the requested service. The questions are listed below.

If all questions are answered, e-referral will either approve or pend the case. If the case pends and we cannot authorize it, we will contact the provider for additional clinical information. Authorization is not a guarantee of payment.

Payment is based on established claim edits. We may retrospectively monitor compliance with authorization requirements.

Applicable procedure codes: \*52441, \*52442

\*CPT Copyright 2022 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

See below for the questions you'll encounter in the e-referral system.

**Q** Is the patient at least 45 years old?

**A**

Possible answers: ☐ Yes ☐ No ☐ N/A

**Q** Does the patient have a documented diagnosis of symptomatic benign prostatic hypertrophy of the LATERAL lobes of the prostate, including but not limited to the following symptoms (A-H)? A. Difficulty starting and stopping urination (hesitancy and straining). B. Decreased strength of the urine stream (weak flow). C. Dribbling after urination. D. Feeling that the bladder is not completely empty. E. An urge to urinate again soon after urinating (urgency). F. Pain during urination (dysuria). G. Nocturia - waking up several times during the night with the urge to urinate. H. Frequent urinary tract infections secondary to urinary obstruction.

**A**

Possible answers: ☐ Yes ☐ No ☐ N/A



**Blue Care  
Network**  
of Michigan

A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association

## Preview questionnaire

### Prostatic urethral lift

For Blue Care Network commercial and BCN Advantage<sup>SM</sup>

Effective March 26, 2023

**Q** Did the patient fail, was unable to tolerate, or had undesirable side effects of pharmacologic interventions to treat BPH, such as the following (A-C)?  
A. Alpha blockers such as Uroxatral, Cardura, Rapaflo, Flomax or Hytrin. B. 5-Alpha Reductase Inhibitors for BPH, such as Avodart or Proscar. C. Combination drugs using both an alpha blocker and a 5-alpha reductase inhibitor.

**A**

Possible answers: ☐ Yes ☐ No ☐ N/A